Key result
Preclinical cardiac reprogramming shows variable feasibility and efficiency for transdifferentiating fibroblasts into cardiomyocytes.
Answers are grounded in this paper and cite their sources.
Review evaluates cardiac transdifferentiation approaches converting fibroblasts into cardiomyocytes, highlighting technological obstacles and safety concerns for clinical translation.
To date, no viable therapeutic options exist for the effective and sustained reversal of cardiac failure, other than heart transplantation and mechanical circulatory assist devices. Therefore, divergent strategies aiming at the de novo formation of contractile tissue, as a prerequisite for the restoration of cardiac pump function, are currently being pursued. Clinical trials involving the transplantation of somatic progenitor cells failed. The search for alternative cell-based strategies to combat the consequences of ischemic injury has sparked widespread interest in the genetic and pharmacologic reprogramming of fibroblasts into cardiomyocytes, harnessing the abundant in vivo pool of cardiac fibroblasts. Here, we provide a comprehensive overview of in vitro and in vivo cardiac reprogramming studies identified in an extensive literature search. We systematically review and evaluate feasibility, efficiency, and reproducibility of the different technologies currently being explored. Finally, we discuss potential safety issues deduced from preclinical studies and identify obstacles that must be overcome before clinical translation.-Klose, K., Gossen, M., Stamm, C. Turning fibroblasts into cardiomyocytes: technological review of cardiac transdifferentiation strategies.
No takes yet. Share an insight, caveat, or question.
Klose et al. (2018) conducted a review in Cardiac failure and ischemic myocardial injury. Genetic and pharmacologic reprogramming of fibroblasts into cardiomyocytes was evaluated on Feasibility, efficiency, reproducibility, and preclinical safety of cardiac transdifferentiation technologies. Genetic and pharmacologic reprogramming of fibroblasts into cardiomyocytes was evaluated for feasibility, efficiency, and safety across preclinical studies, with no quantitative data reported.
Synapse has enriched 10 related papers. Consider them for comparative context: